Treosulfan-based conditioning before hematopoietic SCT: More than a BU look-alike

Bone Marrow Transplantation

Volumn 47, Issue 1, 2012, Pages 5-14

  Danylesko, I ^a   Shimoni, A ^a   Nagler, A ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

acute leukemia; SCT; treosulfan

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; MELPHALAN; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALBERS SCHOENBERG DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CELL DEATH; CELL VIABILITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CONVULSION; CYTOKINE RELEASE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; ENGRAFTMENT; GASTROINTESTINAL SYMPTOM; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC DISEASE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTRANSAMINASEMIA; IMMUNE DEFICIENCY; INTERSTITIAL PNEUMONIA; LEUKEMIA RELAPSE; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MALIGNANT INFANTILE OSTEOPETROSIS; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MICROCHIMERISM; MONOTHERAPY; MORTALITY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOMA; NEUTROPENIA; NON RELAPSE MORTALITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SOLID TUMOR; STOMATITIS; T CELL DEPLETION; VEIN OCCLUSION; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MYELODYSPLASTIC SYNDROMES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855754876     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.88     Document Type: Review

References (91)

1. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29.
2. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
3. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101.
4. Hilger RA, Harstrick A, Eberhardt W, Oberhoff C, Skorzec M, Baumgart J et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 1998; 42: 99-104. (Pubitemid 28267289)
5. Feit PW, Rastrup-Andersen N, Matagne R. Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate. J Med Chem 1970; 13: 1173-1175.
6. Hartley JA, O'Hare CC, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 1999; 79: 264-266. (Pubitemid 29002295)
7. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209-4216.
8. Kopf-Maier P. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro. In Vivo 1998; 12: 275-288. (Pubitemid 28379988)
9. Neuber K, tom Dieck A, Blodorn-Schlicht N, Itschert G, Karnbach C. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo. Melanoma Res 1999; 9: 125-132. (Pubitemid 29331520)
10. Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999; 79: 1487-1493. (Pubitemid 29116809)
11. Reber U, Wullner U, Trepel M, Baumgart J, Seyfried J, Klockgether T et al. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2. Biochem Pharmacol 1998; 55: 349-359. (Pubitemid 28021748)
12. Masding J, Sarkar TK, White WF, Barley VL, Chawla SL, Boesen E et al. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma. Br J Obstet Gynaecol 1990; 97: 342-351. (Pubitemid 20153689)
13. Gropp M, Meier W, Hepp H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 1998; 71: 94-98. (Pubitemid 28492400)
14. Harstrick A, Wilke H, Eberhardt W, Klassen U, Strumberg D, Korn M et al. A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie 1996; 19: 153-156. (Pubitemid 26182874)
15. Wagner HM, Baumgart J, Andreesen R, Reichle A. Tandem high-dose chemotherapy for advanced ovarian carcinoma: dose escalation of treosulfan in combination with carboplatin and etoposide. Bone Marrow Transplant 2000; 26 (Suppl 1): 33.
16. Baynes RD, Parchment R, Dansey RD (ed.). High-dose melphalan, DTIC and treosulfan (MDT) and PBPCT in previously treated metastatic breast and ovarian cancer. 36th Annual Meeting of the American Society of Clinical Oncology; 2000. New Orleans, Louisiana, abstract 585.
17. Munkelt D, Koehl U, Kloess S, Zimmermann SY, Kalaaoui RE, Wehner S et al. Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemother Pharmacol 2008; 62: 821-830.
18. Fichtner I, Becker M, Baumgart J. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer 2003; 39: 801-807. (Pubitemid 36315997)
19. Lanvers-Kaminsky C, Bremer A, Dirksen U, Jurgens H, Boos J. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. Anticancer Drugs 2006; 17: 657-662. (Pubitemid 44265866)
20. Schmidmaier R, Oellerich M, Baumgart J, Emmerich B, Meinhardt G. Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. Exp Hematol 2004; 32: 76-86. (Pubitemid 38064404)
21. Meinhardt G, Dayyani F, Jahrsdorfer B, Baumgart J, Emmerich B, Schmidmaier R. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol 2003; 122: 892-899. (Pubitemid 37174608)
22. Schmidmaier R, Baumgart J, Emmerich B, Meinhardt G. Bryostatin-1 enhances the proapoptotic effect of treosulfan in human acute myeloid leukemia cells, both in cell lines and primary leukemia cells. Onkologie 2002; 28 (Suppl 4): Abstract 574.
23. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005; 35: 233-241. (Pubitemid 40268293)
24. Topaly J, Fruehauf S, Ho AD, Zeller WJ. Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br J Cancer 2002; 86: 1487-1493. (Pubitemid 34548074)
25. Ploemacher RE, Johnson KW, Rombouts EJ, Etienne K, Westerhof GR, Baumgart J et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 2004; 10: 236-245. (Pubitemid 38456202)
26. Westerhof GR, Ploemacher RE, Boudewijn A, Blokland I, Dillingh JH, McGown AT et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000; 60: 5470-5478.
27. Griskevicius L, Gaughan U, Cancparo R, Nilsson C, Hassan M editor. The myeloablative and immunosuppressive properties of treosulfan in mice. ASH Annual Meeting 2001, 2001 Orlando, USA.
28. Schmidmaier R, Baumann P, Emmerich B, Meinhardt G. Evaluation of chemosensitivity of human bone marrow stromal cells-differences between common chemotherapeutic drugs. Anticancer Res 2006; 26: 347-350. (Pubitemid 43206096)
29. Borgmann A, Baldy C, von Stackelberg A, Beyermann B, Fichtner I, Nurnberg P et al. Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol 2000; 17: 635-650.
30. Sjoo F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol 2006; 34: 115-121. (Pubitemid 43069608)
31. van Pel M, van Breugel DW, Vos W, Ploemacher RE, Boog CJ. Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers. Bone Marrow Transplant 2003; 32: 15-22. (Pubitemid 36850275)
32. van Pel M, van Breugel DW, Vos W, Ploemacher RE, Boog CJ. Toward a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers. Bone Marrow Transplant 2004; 33: 153-159. (Pubitemid 38180926)
33. Nagler R, Marmary Y, Krausz Y, Chisin R, Markitziu A, Nagler A. Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1996; 17: 219-224. (Pubitemid 26057311)
34. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003; 78: 181-187. (Pubitemid 37288503)
35. Holler E. Cytokines, viruses, and graft-versus-host disease. Curr Opin Hematol 2002; 9: 479-484. (Pubitemid 35191115)
36. Remberger M, Ringden O, Markling L. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995; 15: 99-104.
37. Remberger M, Ringden O. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation. Transplantation 1995; 60: 1293-1299. (Pubitemid 26005285)
38. Keating MJ. Progress in CLL, chemotherapy, antibodies and transplantation. Biomed Pharmacother 2001; 55: 524-528. (Pubitemid 34008435)
39. Kroger N, Schetelig J, Zabelina T, Kruger W, Renges H, Stute N et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 2001; 28: 643-647. (Pubitemid 33014597)
40. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 725-731. (Pubitemid 38140111)
41. Shimoni A, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Nagler A. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 2007; 48: 2352-2359. (Pubitemid 350258301)
42. Kroger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 2006; 37: 339-344. (Pubitemid 43250466)
43. Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L et al. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/ fludarabine conditioning. J Clin Oncol 2010; 28: 3344-3351.
44. Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA et al. Conditioning with Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant 2010; 17: 341-350.
45. Hilgendorf I, Wolff D, Gromke T, Trenschel R, Elmaagacli AH, Pichlmeier U et al. Retrospective analysis of treosulfanbased conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome. Bone Marrow Transplant 2011; 46: 502-509.
46. Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Holowiecka-Goral A et al. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. Br J Haematol 2008; 142: 284-292. (Pubitemid 351987321)
47. Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2007; 39: 389-396. (Pubitemid 46487303)
48. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322-328. (Pubitemid 43148672)
49. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367-369.
50. Shimoni A, Nagler A. Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immunetherapeutic manipulations. Leukemia 2001; 15: 1967-1975. (Pubitemid 33115006)
51. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021-1028. (Pubitemid 30303589)
52. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763. (Pubitemid 28078275)
53. Casper J, Holowiecki J, Giebel S, Beelen D, Trenschel R, Wandt H et al. Final results of a prospective international phase II allogeneic transplant protocol with Treosulfan/ Fludarabine conditioning in 75 AML patients. Onkologie 2009; 32 (Suppl 4): 29-30.
54. Ruutu T, Beelen DW, Finke J, Holowiecki J, Uharek L, Kienast J et al. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Bone Marrow Transplantation 2009; 43(Suppl 1): 556 (abstract O300).
55. Kroger N, Stelljes M, Bornhauser M, Bethge W, Arnold R, Martin C et al. Treosulfan, etoposide and cyclophosphamide as non TBI-conditioning regimen followed by allogeneic SCT for acute lymphoblastic leukemia. Abstracts of the ASHMeeting 4 December 2010 (Abstract 1327).
56. Bornhauser M, Kiehl M, Siegert W, Schetelig J, Hertenstein B, Martin H et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Haematol 2001; 115: 119-124. (Pubitemid 32995104)
57. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295-1303. (Pubitemid 34177436)
58. Akasheh MS, Freytes CO, Vesole DH. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 26: 1107-1109.
59. Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant 2001; 28: 101-103. (Pubitemid 32707626)
60. Shimoni A, Rand A, Hardan I, Shem-Tov N, Volchek Y, Yerushalmi R et al. (eds). Fludarabine and treosulfan conditioning for allogeneic stem cell transplantation; a dose-intense regimen with limited toxicity. ASH Annual Meeting Abstracts 2010.
61. Uzunel M, Remberger M, Sairafi D, Hassan Z, Mattsson J, Omazic B et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation 2006; 82: 913-919. (Pubitemid 44564037)
62. Niederwieser D, Lange T, Cross M, Basara N, Al-Ali H. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract Res Clin Haematol 2006; 19: 825-838. (Pubitemid 44418026)
63. Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001; 97: 1560-1565. (Pubitemid 32217216)
64. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071-1078. (Pubitemid 34525573)
65. Shimoni A, Giralt S, Khouri I, Champlin R. Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect. Curr Oncol Rep 2000; 2: 132-139.
66. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588-3594. (Pubitemid 46572554)
67. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454. (Pubitemid 37314788)
68. Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J et al. Analysis of outcome following allogeneic haemopoieticstem cell transplantation for myeloma using myeloablative conditioning-evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005; 128: 496-502. (Pubitemid 40283167)
69. Shimoni A, Rand A, Hardan I, Shem-Tov N, Volchek Y, Hannah M et al. (ed.). Second allogeneic hematopoietic stemcell transplantation using fludarabine treosulfan conditioning regimen in patients previously treated with busulfan-based regimens: myeloablation with acceptable toxicity. ASH Annual Meeting Abstracts 2009.
70. Barrett AJ, Savani BN. Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol 2008; 45: 49-59.
71. Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008; 14: 246-255.
72. Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004. (Pubitemid 35001229)
73. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010; 28: 405-411.
74. Baronciani D, Rambaldi A, Iori AP, Di Bartolomeo P, Pilo F, Pettinau M et al. Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. Am J Hematol 2008; 83: 717-720.
75. Greystoke B, Bonanomi S, Carr TF, Gharib M, Khalid T, Coussons M et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol 2008; 142: 257-262. (Pubitemid 351987307)
76. Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones RJ, Woolfrey A et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and b-thalassemia. Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2003; 9: 519-528. (Pubitemid 38351796)
77. Bertaina A, Bernardo ME, Mastronuzzi A, La Nasa G, Locatelli F. The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation. Ann N Y Acad Sci 2010; 1202: 141-148.
78. Bernardo ME, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol 2008; 143: 548-551.
79. Beier R, Hoenig M, Schegel G, Holter W, Stachel D et al., editor Treosulfan-based conditioning in children: retrospective analysis of the German and Austrian experience. 36th Annual Meeting of the European Group for Blood and Marrow Transplantation; 26th Meeting of the EBMT Nurses Group; 9th Meeting of the EBMT Data Management Group; 2nd EBMT Quality Management Meeting; 4th Patient & Family Day. Vienna, Austria; 21 March 2010-24 March 2010. Oral Session 11: Paediatric issues 1. 2010.
80. Peccatori J, Forcina M, Bernardi M, Crocchiolo R, Messina C et al., editor In-vivo T-regs generation by rapamycin-mycophenolate-ATG as a new platform for GvHD prophylaxis in T-cell repleted unmanipulated haploidentical peripheral stem cell transplantation: results in 59 patients. 36th Annual Meeting of the European Group for Blood and Marrow Transplantation 26th Meeting of EBMT Nurses Group 9th Meeting of the EBMT Data Management Group 2nd EBMT Quality Management Meeting 4th Patient & Family Day 2010. Vienna, Austria.
81. Floersheim GL. A comparative study of the effects of antitumour and immunosuppressive drugs on antibody-forming and erythropoietic cells. Clin Exp Immunol 1970; 6: 861-870.
82. Brodsky RA. High-dose cyclophosphamide for autoimmunity and alloimmunity. Immunol Res 2010; 47: 179-184.
83. Nath CE, Shaw PJ, Montgomery K, Earl JW. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 2007; 64: 151-164. (Pubitemid 47063242)
84. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B. et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525-530. (Pubitemid 19135219)
85. Nieto Y, Vaughan WP. Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 2004; 33: 259-269. (Pubitemid 38256557)
86. Casper J, Knauf W, Blau I, Ruutu T, Volin L, Wandt H et al. Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. Ann Hematol 2004; 83(Suppl 1): S70-S71.
87. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone Marrow Transplant 1995; 15: 869-871.
88. Vergnon JM, Boucheron S, Riffat J, Guy C, Blanc P, Emonot A. Interstitial pneumopathies caused by busulfan. Histologic, developmental and bronchoalveolar lavage analysis of 3 cases. Rev Med Interne 1988; 9: 377-383.
89. Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996; 37: 247-253.
90. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519-1525.
91. Weatherall DJ, Galton DA, Kay HE. Busulphan and bone marrow depression. Br Med J 1969; 1: 638.